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1. Participants 
There were n = 243 male-only participants. Most (217, 89%) were students from a 
southern Californian college. Non-student participants were community members from 
surrounding cities. n = 125 of subjects were randomly assigned to receive a standard dose 
of T and n = 118 received placebos of matched viscosity in a double blind exogenous 
administration paradigm.  
 
Pre-screening criteria excluded everyone with relevant medical and psychological 
conditions (5α-reductase deficiency, Klinefelter’s syndrome, brain tumor, cancer, 
psychiatric diagnosis/diagnoses, high blood pressure, liver disease, kidney disease, 
angina, cancer, hepatitis, renal/kidney impairment, history of epileptic seizures and 
hypersensitivity to soy/ alcohol), subjects using prescription drugs that may interfere with 
the study (oxyphenbutazone, insulin, corticosteroids, opioids), subjects who self-reported 
consuming illegal drugs or excessive alcohol in the last 24 hours and non-native English 
speakers.  
 
Personal, demographic, and treatment expectancy characteristics of the two treatment 
groups are summarized in table S1 (note that 5 subjects did not report their age and were 
therefore excluded from all analyses in which age is used as a control variable). The right 
column of Table S1 also reports the p-value of two sample t-tests for differences between 
T and placebo group characteristics (a check on whether random assignment resulted in 
balance on all such variables). Two subjects (one from each treatment group) self-
reported taking T treatment on a regular basis; all analyses include these subjects and are 
robust to excluding them.  
 
Table S1: Self-reported demographic data summary (standard errors in 
parentheses) 
 All T Placebo p-values for t-test of difference 
N 243 125 118  
Age 23.63 
(0.46) 
24.42 
(0.77) 
22.78 
(0.49) 
0.08 
Left-handed (proportion) 0.074 
(0.02) 
0.064 
(0.02) 
0.085 
(0.03) 
0.54 
Heterosexual (proportion) 0.90 
(0.02) 
0.91 
(0.03) 
0.89 
(0.03) 
0.56 
Treatment expectancy1  2.76 
(0.06) 
2.67 
(0.08) 
2.85 
(0.09) 
0.16 
Married (proportion) 0.08 
(0.02) 
0.09 
(0.03) 
0.08 
(0.03) 
0.74 
 
In a relationship (proportion)  0.38 
(0.03) 
0.34 
(0.05) 
0.42 
(0.04) 
0.20 
Has children 0.06 
(0.02) 
0.08 
(0.02) 
0.04 
(0.02) 
0.23 
Personal monthly income2  2.05 
(0.11) 
2.02 
(0.14) 
2.07 
(0.16) 
0.84 
1 5 point scale, 1 = definitely did not get testosterone, 2 = probably not, 3 = unsure, 4 = probably got testosterone, 5 = 
definitely got testosterone 
 
2 5 point scale, 1 = under $500/month, 2 = $501-$1,000, 3 = $1,001-$1,500/month, 4 = $1,501-$2,000/month 5 = over 
$2001/month 
2. Hormonal assay procedure 
Salivary steroids (estrone, estradiol, estriol, testosterone, androstenedione, DHEA, 5-
alpha DHT, progesterone, 17OH-progesterone, 11-deoxycortisol, cortisol, cortisone, and 
corticosterone) were measured by LC-MS/MS using an AB Sciex Triple Quad 5500.  
Internal standards were added to 1 ml of saliva and the steroids then extracted by C18 
column chromatography with 0.1 M NH4OH wash followed by 10% acetone.  Steroids 
were eluted from the SPE with 10% methanol in acetone and dried under nitrogen. The 
dried samples were subjected to derivatization—the process of transforming a compound 
into a derivative product of similar chemical structure—with pyridine-3-sulfonyl chloride 
for the estrogens (estrone (E1), estradiol (E2), and estriol (E3)) as outlined by Xi and 
Spink (2008). 40 µL sodium bicarbonate (50mM, pH 10) and 40 µL pyridine-3-sulfonyl 
chloride (3 mg/mL in acetonitrile) were added to the dried samples, and incubated at 
60oC for 10 minutes.  After derivatization, the samples were diluted with 80 µL of water 
and injected for LC-MS/MS analysis with analytical separation performed on an Agilent 
Poroshell 120 EC-C8 column and ionization by atmospheric pressure chemical ionization 
(APCI) in the positive ionization mode. Table S2 lists each analyte along with its 
validation results for the lower limit of quantitation (LLOQ is jargon for the lowest level 
of detection with coefficients of variation (CVs) < 20% over the linear range), linear 
range, and the inter-assay precision from the highest concentration to the LLOQ within 
the linear range. When salivary hormone levels of participants were below their LLOQ, 
we assigned values halfway between zero and their respective LLOQ (note that the true 
quantities of the hormone in the sample are never zero, even when they do not reach the 
detection threshold). 
Table S2: Detection levels, precision and normality tests of hormonal assay  
 
Analyte LLOQ Range Precision 
Proportion 
undetected, 
pre-
treatment 
sample A 
Proportion 
undetected, 
first post-
treatment 
sample B 
K-S test p-
value 
K-S test (log) 
p-value 
Estrone 
 pg/mL 
0.5 0.5 - 510 8.7 - 13.7% 0.132 0.257 <0.01 0.56 
Estradiol 
 pg/mL 
0.3 0.3 - 510 4.3 - 18.7% 0.128 0.329 0.06 0.88 
Testosterone 
pg/mL 
3.0 3.0 - 5100 3.0 - 18.1% 0 0.008 <10-20 <0.01 
Androstenedione 
pg/mL 
5.0 5.0 - 2300 5.2 - 6.6% 0 0.008 <10-20 0.008 
DHEA 
 pg/mL 
20.0 20.0 - 1800 4.1 - 15.2% 0.004 0.012 0.002 0.98 
DHT 
 pg/mL 
10.0 10.0 - 920 3.6 - 17.7% 0.786 0.473 <10-11 0.02 
Progesterone 
pg/mL 
10.0 10.0 - 10000 4.8 - 10.8% 0.794 0.753 <0.01 0.03 
17OH-
Progesterone 
pg/mL 
5.0 5.0 - 630 3.9 - 13.8% 0.004 0.061 0.003 0.98 
11-Deoxycortisol 
pg/mL 
5.0 5.0 - 410 6.8 - 16.6% 0.132 0.473 <0.01 0.04 
Cortisol 
 ng/mL 
0.1 0.1 - 52 5.1 - 17.9% 0 0.008 <0.01 0.92 
Cortisone 
 ng/mL 
0.1 0.1 - 81 4.1 - 14.9% 0 0.008 0.07 0.59 
Corticosterone 
pg/mL 
5.0 5.0 - 1800 4.6 - 17.5% 0.313 0.312 <0.01 0.08 
Aldosterone 
 pg/mL 
10.0 10.0 - 560 8.9 - 18.8% 0.272 0.272 <0.06 0.39 
Melatonin 
 pg/mL 
2.5 2.5-10000 5.2 - 15.9% 0.502 0.500 0.07 0.14 
 
Note: P-values are calculated using a Kolmogorov-Smirnov test for the distributions of the second saliva sample compared to 
Gaussian, and for the log-transform (the null hypothesis is normal Gaussian distribution). 
 
 3. Hormonal changes following treatment and manipulation check 
As expected, there were significant post-treatment differences between groups with 
respect to all hormones influenced by T treatment, either as an upstream 
(androstenedione) or downstream (5-alpha DHT) metabolite of T (S1). There was also a 
decrease in progesterone 170H resulting from an increase in T (which is common, 
according to personal communication from ZRT Laboratories chief scientist Dr. David 
Zava). The changes in saliva T measures were similar in magnitude to those reported in 
previous studies following topical gel administration of T and progesterone, e.g. (S2, S3).   
We observed no significant differences between treatment groups in hormones that were 
not expected to change following short-term T treatment (e.g., aldosterone, cortisol, 
cortisone, melatonin) in all four saliva measurements throughout the experiment (i.e., the 
pre-treatment and the three post-treatment measurements). The pre-treatment and first 
post-treatment mean hormonal saliva levels are summarized in table S3; note that 
differences between morning and afternoon hormonal levels were affected by diurnal 
cycles in both treatment groups.  
From assays conducted during the first 13 (out of 17) sessions of the study, we noted that 
72 out of 184 pre-treatment baseline saliva samples (in both treatment groups) presented 
measurements with higher T level that are expected in normal young men (greater than 
400 pg/mL). All other measurements (including T metabolites) were hormonally typical. 
The effects of T on the CRT were robust to excluding the subjects with abnormal 
measurements (see below).  
We traced the cause of these abnormal measurements to T gel transfer to common 
surfaces (e.g., door knobs, mouse pads). Crucially, the high measurements were caused 
by local spread of T into saliva tubes, but physiological levels were unaffected by 
superficial contact with the dry nuisance T gel, as (a) we observed normal pre-treatment 
levels of T metabolites, namely DHT and androstenedione in all subjects; (b) none of the 
placebo group participants showed abnormally high values of T metabolites in any of the 
post-treatment measurements; (c) Only five out of 118 subjects from the placebo group 
showed consistently elevated T measurements in all of the 3 post-treatment saliva 
samples; (d) previous investigations found that interpersonal T transfer is highly unlikely 
even with skin-to-skin contact, (S4). Thus, we found convergent evidence that biofluid 
levels were unaffected by superficial contact. This conclusion was supported by ZRT 
Laboratories chief scientist Dr. David Zava. 
In response to this finding during the course of the experimental period, we identified all 
surfaces and objects through which T could spread in the facility and improved sterile 
isolation protocol to eliminate the spread of the dried T gel. This protocol included 
thorough cleaning of keyboards, computer mice, chair backs, displays, and all doorknobs 
with a bleach-alcohol solution after each session as well as asking subjects to carefully 
wipe hands with a wet tissue before collecting each saliva sample. New pens were used 
for each session while all previously used pens were removed from testing area. 
Clipboards and other miscellaneous objects that participants did or could interact with 
were cleaned, and an aerosol "air sanitizer" that bonds to VOCs (volatile organic 
compounds) was sprayed into the air. Following the adoption of this strict sterilization 
protocol, we found a drastic reduction in incidence of high T samples in the pre-treatment 
measurements, to a total of 5 participants out of 58 in the following four sessions 
(sessions 14-17).  
Finally, we conducted additional robustness checks by examining the effects of T on the 
CRT when (a) excluding subjects with pre-treatment saliva T of greater than 400 pg/ml 
from both treatment groups; (b) excluding placebo subjects with post-treatment saliva T 
(sample B) greater than 400 pg/ml; (c) excluding all subjects in either condition (a) or 
(b); and (d) repeating the analysis with a more conservative cutoff of 250 pg/ml. We 
found that the effect of T administration on the CRT were highly significant (all 
p’s<0.02) regardless of the exclusion criteria used.  
Table S3: hormone panel data measurements log(pg/mL) summary statistics 
(standard errors in parentheses) 
 
Placebo 
 
Testosterone 
Two-tailed p-value 
from t-test of T-
Placebo equality  
Sampling time1 9am 2pm 9am 2pm 9am 2pm 
Testosterone 5.743 5.111 5.580 8.373 0.267 1.06E-13 
 
(0.094) (0.085) (0.084) (0.151) 
  Androstenedione 4.510 4.205 4.525 5.462 0.634 3.11E-09 
 
(0.039) (0.044) (0.034) (0.084) 
  DHT 1.984 1.867 1.905 3.482 0.745 2.38E-06 
 
(0.069) (0.051) (0.060) (0.114) 
  Progesterone 1.937 2.002 1.829 1.883 0.36 0.41 
 
(0.058) (0.064) (0.052) (0.055) 
  Progesterone170H 3.245 2.675 3.217 2.463 0.792 0.008 
 
(0.050) (0.058) (0.049) (0.058) 
  Estrone -0.088 -0.557 -0.007 -0.389 0.29 0.42 
 
(0.063) (0.066) (0.064) (0.056) 
  Estradiol -0.743 -1.158 -0.766 -1.066 0.86 0.44 
 
(0.052) (0.059) (0.054) (0.054) 
  DHEA 5.198 4.570 5.116 4.557 0.30 0.76 
 
(0.053) (0.058) (0.051) (0.054) 
  Deoxycortisol11 2.579 1.650 2.568 1.584 0.66 0.35 
 
(0.079) (0.072) (0.083) (0.064) 
  Cortisol 1.047 0.062 1.045 0.077 0.68 0.81 
 (0.058) (0.065) (0.057) (0.058) 
  Cortisone 2.539 1.952 2.539 2.003 0.70 0.76 
 
(0.030) (0.060) (0.034) (0.050) 
  Corticosterone 2.442 1.274 2.646 1.290 0.37 0.76 
 
(0.126) (0.065) (0.123) (0.060) 
  Aldosterone 2.640 2.516 2.634 2.395 0.82 0.14 
 
(0.067) (0.071) (0.068) (0.066) 
  Melatonin 1.045 0.276 1.221 0.353 0.27 0.23 
 
(0.093) (0.029) (0.101) (0.051) 
  1 Main effects of time (afternoon vs. treatment) are due to the diurnal cycles of the hormones (S5-S7) 
 
4. Results 
4.1 Mood questionnaire 
Table S4 shows a modest decrease in both affect measures over time (morning vs. 
afternoon), and no treatment or time x treatment interaction, indicated by the output of 2-
way analysis of variance (ANOVA) with an interaction term, ruling out this indirect way 
in which T might affect cognition and behavior. Three subjects did not answer all of the 
negative affect items in their questionnaires, and five subjects did not complete all of the 
positive affect items; these subjects were excluded from analyses that include these scales 
as control variables. 
Table S4: Positive / negative affect (PANAS-X) summary statistics 
 All Testosterone Placebo ANOVA: p-values 
Time Morning Afternoon Morning Afternoon Morning Afternoon T Time T x time 
Positive affect 2.72 
(0.05) 
2.61 
(0.06) 
2.72 
(0.06) 
2.63 
(0.08) 
2.72 
(0.07) 
2.60 
(0.09) 
0.85 
 
0.16 0.85 
Negative affect 1.53 
(0.04) 
1.45 
(0.04) 
1.53 
(0.06) 
1.46 
(0.05) 
1.53 
(0.05) 
1.43 
(0.05) 
0.77 
 
0.13 
 
0.84 
 
4.2 Cognitive reflection test 
CRT scores were comparable to those previously found in equivalent samples (Brañas-
Garza et al. 2015), although at the high end of the range. This is likely due to high 
analytical skill in the sampled college population (conducted in one of the top ranked 
schools in the US). We tested our main hypothesis by estimating linear regression models 
with the three-item total CRT score as the dependent variable (DV). All of the analyses 
were conducted using the function ‘lm’ implemented in ‘R’ and the results are 
summarized in table S5.  Model A1 included only treatment (testosterone=1, placebo=0) 
as an independent variable (IV); Model A2 also included the math task performance. 
Model A3 also included age, positive and negative affect, treatment expectancy and the 
right hand digit ratios (the results hold when the left hand or the average between the two 
hands are used). Model A4 included all of the IVs of model A3 with the addition of all of 
the hormonal levels that were not affected by the treatment, as measured from the first 
post-treatment saliva sample (i.e., the second overall sample); all of the results hold when 
the measurements are replaced with the second post-treatment saliva sample (i.e., the 
third overall measurement, see table S7).  
In models (B1-B4), summarized in table S6, we repeated the analyses of models (A1)-
(A4), where the binary treatment variable was replaced by the measurements of the 
hormones that are affected by the treatment (T, DHT, androstenedione and progesterone 
170H).  
 
Finally, models (C1-C2) in Table S7 replicate the results of models (A4) and (B4) using 
the hormonal measurements of from the second post-treatment (and third overall) saliva 
sample. 
 
4.3 CRT, question level 
We further examined the effect of T on each of the three CRT questions separately. For 
each question, we classified the responses as either (a) an intuitive incorrect answer, i.e., 
10 cents in the “bat and the ball” question, 100 minutes in the “widgets” question, 24 in 
the “lily pads” question; (b) the reflective, correct answer, i.e., 5 cents in the “bat and the 
ball” question, 5 minutes in the “widgets” question, 47 in the “lily pads” question; or (c) 
another incorrect answer, i.e., different than in (a) or (b).  
We estimated two logistic regressions for each question, one that included a binary DV 
that was equal “1” for incorrect intuitive answers and the other included a binary DV that 
was equal “1” for correct answers. The analysis revealed that the likelihood of the 
incorrect intuitive response was significantly greater in the T group for each one of the 
three questions and that the proportion of correct answers was greater in the placebo 
group for each of the CRT questions in isolation (see Fig. 1 and table S8). Intriguingly, 
both of the subjects who self-reported taking T supplements regularly (one from each 
group) scored 0 out of 3 in the CRT, and all of their answers were the incorrect intuitive 
ones. Although the latter finding suggests that long term T treatment might have larger 
effects on CRT performance compared to a single dose, the small number of such 
subjects does not allow for making inferences that can be considered more than anecdotal. 
Moreover, as the long-term treatment was not assigned at random, causality cannot be 
inferred from these two data points (e.g., it is possible that subjects with low CRT scores 
are more likely to use T supplements, rather than vice versa). 
 Table S5: Linear regression, dependent variable: CRT score. Hormonal 
measurements are log transformed and taken from the first post-treatment saliva 
sample. 
 
(A1) (A2) (A3) (A4) 
Treatment 
-0.438*** 
(0.142) 
-0.441*** 
(0.136) 
-0.356** 
(0.142) 
-0.296** 
(0.145) 
     
Math 
 
0.079*** 
(0.017) 
0.078*** 
(0.017) 
0.073*** 
(0.018) 
Negative affect 
  
0.058 
(0.132) 
-0.049 
(0.136) 
Positive affect 
  
-0.142* 
(0.075) 
-0.139* 
(0.076) 
Age 
  
-0.030*** 
(0.010) 
-0.035*** 
(0.010) 
    Treatment 
expectancy 
  
0.062 
(0.076) 
0.080 
(0.076) 
 
Digit ratio (right) 
  
-1.456 
(2.029) 
-0.901 
(2.038) 
 
Estrone 
   
0.017 
(0.114) 
Estradiol 
   
0.147 
(0.119) 
DHEA 
   
-0.139 
(0.149) 
Progesterone 
   
-0.012 
(0.108) 
Deoxycortisol11 
   
0.215 
(0.133) 
Cortisol 
   
-0.278* 
(0.228) 
Cortisone 
   
-0.300* 
(0.298) 
Corticosterone 
   
0.052 
(0.120) 
Aldosterone 
   
0.209** 
(0.098) 
Melatonin 
   
0.0002 
(0.154) 
Constant 
2.102*** 
(0.102) 
1.248*** 
(0.203) 
3.425* 3.692 
(1.965) (2.152) 
Observations 243 243 229 227 
R2 0.038 0.122 0.150 0.205 
Adjusted R2 0.034 0.115 0.123 0.140 
Residual Std. 
Error 
1.109 (df = 241) 1.062 (df = 240) 1.050 (df = 221) 1.031 (df = 209) 
F Statistic 9.447*** (df = 1; 241) 
16.665*** (df = 2; 
240) 
5.582*** (df = 7; 221) 
3.173*** (df = 17; 
209) 
Note: *p < 0.1 **p < 0.05 ***p < 0.01 
 
 Table S6: Linear regression, dependent variable: CRT score. Hormonal 
measurements are log transformed and taken from the first post-treatment saliva 
sample. 
 
(B1) (B2) (B3) (B4) 
Testosterone 
-0.205*** 
(0.067) 
-0.202*** 
(0.064) 
-0.184*** 
(0.067) 
-0.198*** 
(0.067) 
Androstenedione 
0.226 
(0.165) 
0.180** 
(0.159) 
0.150 
(0.164) 
0.204 
(0.169) 
DHT 
-0.006 
(0.087) 
-0.046 
(0.084) 
0.073 
(0.084) 
0.089 
(0.085) 
Progesterone170H 
-0.034 
(0.117) 
-0.043 
(0.112) 
-0.073 
(0.115) 
-0.055 
(0.127) 
Math 
 
0.076*** 
(0.017) 
0.075*** 
(0.018) 
0.073*** 
(0.018) 
Negative affect 
  
0.007 
(0.131) 
-0.095 
(0.136) 
Positive affect 
 
 -0.143
** 
(0.075) 
-0.148* 
(0.076) 
 
Age 
 
 
-0.029*** 
(0.010) 
-0.033*** 
(0.010) 
Treatment expectancy 
 0.067 
(0.076) 
0.078 
(0.076) 
  
Digit ratio (right) 
  
-0.547 
(2.018) 
0.058 
(2.032) 
    
Estrone 
 
  
0.034 
(0.114) 
Estradiol 
  
0.157 
(0.112) 
 
DHEA 
   
-0.141 
(0.149) 
Progesterone 
   
-0.010 
(0.107) 
Deoxycortisol11 
   
0.211 
(0.133) 
Cortisol 
   
-0.314 
(0.229) 
Cortisone 
   
-0.274 
(0.306) 
 
Corticosterone 
   
0.078 
(0.119) 
Aldosterone 
   
0.222** 
(0.096) 
Melatonin 
   
0.038 
(0.155) 
Constant 
2.265*** 
(0.503) 
1.564** 
(0.506) 
2.997 
(2.031) 
2.840 
(2.181) 
Observations 241 241 227 227 
R2 0.056 0.133 0.164 0.227 
Adjusted R2 0.040 0.115 0.125 0.152 
Residual Std. Error 1.098 (df = 236) 1.054 (df = 235) 1.04 (df = 216) 1.024 (df = 206) 
F Statistic 3.485*** (df = 4; 236) 
7.233*** (df = 5; 
235) 
4.24*** (df = 10; 216) 
3.031*** (df = 20; 
206) 
Note: *p < 0.1 **p < 0.05 *** p < 0.01 
 
 Table S7: Linear regression, dependent variable: CRT score. Hormonal 
measurements are log transformed and taken from the second post-treatment saliva 
sample. 
 
(C1) (C2) 
Treatment 
-0.314** 
(0.148) 
 
 
Testosterone 
 
-0.169** 
(0.063) 
Androstenedione 
 
0.002 
(0.156) 
DHT 
 
0.167 
(0.104) 
Progesterone170H 
 
-0.225 
(0.139) 
Math 
0.075*** 
(0.018) 
0.075*** 
(0.018) 
Negative affect 0.014 
(0.136) 
0.014 
(0.135) 
 
Positive affect 
-0.099 
(0.077) 
-0.103 
(0.076) 
Age 
-0.028*** 
(0.010) 
-0.032*** 
(0.011) 
Treatment expectancy 
0.054 
(0.077) 
0.043 
(0.076) 
Digit ratio (right) 
-1.648 
(2.078) 
-0.711 
(2.064) 
Estrone 
-0.076 
(0.110) 
-0.040 
(0.109) 
Estradiol 
0.125 
(0.124) 
0.163 
(0.124) 
DHEA 
-0.137 
(0.131) 
-0.099 
(0.130) 
Progesterone 
0.124 
(0.127) 
0.124 
(0.125) 
Deoxycortisol11 
0.285 
(0.131) 
0.393** 
(0.137) 
Cortisol 
-0.218 
(0.167) 
-0.329* 
(0.172) 
Cortisone 
-0.218 
(0.167) 
-0.209 
(0.225) 
Corticosterone 
0.293* 
(0.146) 
0.322** 
(0.145) 
Aldosterone 
0.069 
(0.149) 
0.042 
(0.147) 
Melatonin 
-0.015 
(0.165) 
0.048 
(0.165) 
Constant 
3.548 
(2.189) 
3.588 
(2.217) 
Observations 228 228 
R2 0.200 0.234 
Adjusted R2 0.135 0.160 
Residual Std. Error 1.039 (df = 210) 1.023 (df = 207) 
F Statistic 3.086*** (df = 17; 211) 3.164*** (df = 20; 207) 
Note: *p<0.1**p<0.05***p<0.01 
 
Table S8: CRT score response frequencies and statistics by question 
 Testosterone Placebo Logistic regression 
stats: (intuitive = 1) 
Logistic regression 
stats (deliberate = 
1) 
Question % intuitive  % deliberate  % intuitive % deliberate z p-value z p-value 
Bat and ball 0.42 0.53 0.31 0.66 2.05 0.04 -2.69 0.009 
Widgets 0.42 0.45 0.30 0.59 2.057  0.04 -2.64  0.008 
Lili pads 0.20 0.67 0.10 0.82 2.24 0.02 -2.77 0.006 
 
4.4 Response times  
The T group responded 6.74 seconds slower on average when making correct answers (T: 
50.97s, placebo: 44.23s) and 7.11 second faster on average when providing incorrect 
answers (T: 51.35s, placebo: 58.46s). A Kolmogorov-Smirnov test revealed that the 
response times (RT) were highly non-Gaussian (p < 10-18).  Therefore the values were 
log-transformed for normalization purpose before statistical tests (post-transformation 
Kolmogorov-Smirnov test, p = 0.25). To formally examine the treatment’s effect on RT, 
we estimated linear mixed model regressions with log(RT) as the dependent variable 
(DV), and treatment (binary variable), error indicator (incorrect = 1, correct = 0) and the 
interaction between those binary treatment and error dummies as independent variables 
(fixed effects). Random effects of subject and question number were also included (see 
table S9). The main treatment coefficient (models D1 and D2) was insignificant, 
implying that T subjects did not differ in their general response times relative to placebo. 
However, the interaction between treatment and incorrect answers was negative and 
marginally significant at the p < 0.10 level. That is, T group subjects adopted their 
incorrect intuitions more rapidly when providing incorrect answers in the CRT. 
Additional simple slope analyses conducted separately for correct trials (456 
observations) and incorrect trials (273 observations) revealed a marginally significant (at 
the p < 0.10 level) positive treatment effect in correct trials, implying that T treated 
participants were slower to respond when correct (model D3), and a negative, yet 
insignificant treatment effect in incorrect trials (model D4). The absence of statistically 
significant treatment effects in the latter might be due to the small number of 
observations and the noisiness of the RT measure in a task such as the CRT. 
We did not directly record response time per-item in the math task. However, as the task 
was timed (5 minutes per participant) we could approximate the average response time 
per subject by dividing 300 (5 minutes) by the number of questions. We did not find 
differences between the two groups in this measure (P: 22.3 Sec; T = 21.4 Sec), t(241) = 
1.034, p > 0.30). 
  
 Table S9: Mixed model linear regression. Dependent variable: logged response 
times, with subject and question random intercept  
 
 
Dependent variable: 
  
 
log(Response time) 
 
(D1) (D2) (D3) (D4) 
 All trials All trials Correct only Incorrect only 
Treatment 0.054 0.125 0.135* -0.052 
 
(0.065) (0.078) (0.078) (0.105) 
Incorrect 
 
0.089 
  
  
(0.086) 
  
Treatment:Incorrect 
 
-0.189* 
  
  
(0.115) 
  
Constant 3.605*** 3.578*** 3.596*** 3.732*** 
 
(0.071) (0.076) (0.119) (0.157) 
 
Observations 729 729 456 273 
Log Likelihood -776.893 -778.680 -461.583 -303.984 
Akaike Inf. Crit. 1,563.785 1,571.360 933.165 617.968 
Bayesian Inf. Crit. 1,586.743 1,603.502 953.778 636.016 
Note: *p < 0.1; **p < 0.05; ***p < 0.01 
 
 
 
 
 
Figure S1: Response times (in seconds) as a function of treatment and response 
correctness. Error bars denote 95% confidence intervals.  
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